Last checked at 4 Dec 2020 07:00
Tissue Regenix Group plc
Board changes
Leeds, 4 December 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group",) the regenerative medical devices company, announces its intention to appoint Brian Phillips and Trevor Phillips (no relation) as independent Non-Executive Directors of Tissue Regenix.
Brian Phillips is an entrepreneurial investment professional with over 25 years' experience. Brian is the current Principal of Ethos partners which he co-founded in 2018 to assist individuals in establishing a portfolio of assets under private equity investments. Prior to this, Brian was Chief Investment Officer at Greenhill Capital Partners Europe LLP where he was responsible for setting up their UK business (2006-2010) and Managing Director of LGV Capital (2000-2006). Brian holds a B.Acc from Glasgow University and qualified as a Chartered Accountant with KMPG.
Trevor Phillips is the current Chairman of the Board at NEPeSMO and has extensive experience in the UK and US in corporate development, M&A and operations in the pharmaceutical and life science industries including previously held positions as Executive Chairman of hVIVO (2017-2020), Chief Operating Officer for Vectura Group plc (2011-2017) and former CEO and COO of Critical Therapeutics, Inc. (2002-2008). Trevor holds a BSc, Microbiology from the University of Reading, a PhD, Microbial Biochemistry from Swansea University and an MBA from Henley Business School.
Both Brian and Trevor will be appointed to the board of Tissue Regenix following the completion of the necessary regulatory due diligence in accordance with the AIM Rules. Following appointment, Brian Phillips will Chair the Audit Committee and Trevor Phillips will Chair the Renumeration Committee.
Alongside this, after many years of service, Alan Miller and Randeep Grewal have notified the Board of their resignation as Non-Executive Directors with immediate effect.
Jonathan Glenn, Interim Chair of Tissue Regenix, commented: "As we focus on leveraging our operational capabilities and driving the commercialisation of our product pipelines, I am pleased to welcome Brian and Trevor to the Board who both bring a wealth of experience that will be crucial in shaping the future strategy and success of the Group. I would like to extend my thanks to Alan and Randeep who have been highly committed Board members and have supported the Group for many years."
For more Information:
Tissue Regenix Group plc Caitlin Pearson Head of Communications |
Tel: 0330 430 3073 |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price | Tel: 0207 710 7600
|
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.